Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries and its subsidiaries have launched Imatinib Mesylate Tablets (therapeutic equivalent to Gleevec for indications approved by the FDA) in US market. Sun Pharma’s subsidiary received final approval for Imatinib Mesylate from FDA in December 2015. Being a First-to-File product, it was granted 180 days of marketing exclusivity by FDA from the time of its launch.

As part of this launch, in addition to strengthening distribution in USA, the company has rolled-out unique Sun Pharma Imatinib Mesylate Savings Card program. This program aims to deliver greater access to the drug for patients who have a commercial insurance but their out-of-pocket may exceed an affordable amount.

Sun Pharma has also launched an exclusive patient website providing detailed information about its Imatinib Mesylate, approved indications, side effects etc. Additionally, the website features detailed FAQs on the product.